a Real World Evidence , GlaxoSmithKline , London , UK.
b Real World Evidence , GlaxoSmithKline , Research Triangle Park , North Carolina , USA.
COPD. 2017 Aug;14(4):382-388. doi: 10.1080/15412555.2017.1313827. Epub 2017 Jun 1.
Blood eosinophil counts may be predictive of corticosteroid response in chronic obstructive pulmonary disease (COPD) patients. However, little is known about measurement stability, which is important for understanding the utility of blood eosinophil counts as a potential biomarker. We evaluated the stability of blood eosinophil counts over 1 year in a population-based cohort of patients with COPD in primary care. Patients were aged ≥ 40 years with forced expiratory volume in 1 second/forced vital capacity < 0.7 and ≥ 1 blood eosinophil measurement taken during a period of stable disease within 6 months of a COPD diagnosis code recorded between January 1, 2010 and December 31, 2012. Generalized linear mixed models were fitted to log-transformed data to estimate the between-(s) and within-patient (s) variance in eosinophil count; an intra-class correlation coefficient R was calculated (s/[s + s]). A sensitivity analysis was performed from which patients who were prescribed systemic corticosteroids or antibiotics at any time during follow-up were excluded. All models were adjusted for age, gender, smoking status, and asthma history. Overall, 27,557 patients were included in the full cohort (51.5% male, mean age [standard deviation] 71.1 [10.6] years) and 54% of patients had ≥ 2 eosinophil measurements (median 2 [interquartile range 1]) during follow-up. For the full cohort, R = 0.64, and in the sensitivity analysis subgroup, R = 0.70, mainly due to a decrease in s. For patients with COPD in primary care, eosinophil measurements demonstrated reasonable repeatability over 1 year, which increased after exclusion of patients who were prescribed systemic corticosteroids or antibiotics.
血液嗜酸性粒细胞计数可能可预测慢性阻塞性肺疾病(COPD)患者对皮质类固醇的反应。然而,对于测量稳定性了解甚少,这对于理解血液嗜酸性粒细胞计数作为潜在生物标志物的实用性很重要。我们评估了初级保健中 COPD 患者的人群中血液嗜酸性粒细胞计数在 1 年内的稳定性。这些患者年龄≥40 岁,用力呼气量/用力肺活量<0.7,且在 COPD 诊断代码记录的 6 个月内,在疾病稳定期间至少有 1 次血液嗜酸性粒细胞计数。对对数转换后的数据拟合广义线性混合模型,以估计嗜酸性粒细胞计数的组间(s)和患者内(s)方差;计算了组内相关系数 R(s/[s + s])。进行了敏感性分析,排除了在随访期间任何时候服用全身皮质类固醇或抗生素的患者。所有模型均根据年龄、性别、吸烟状况和哮喘史进行了调整。总体而言,共有 27557 例患者纳入了全队列(51.5%为男性,平均年龄[标准差]71.1[10.6]岁),其中 54%的患者在随访期间有≥2 次嗜酸性粒细胞计数(中位数为 2[四分位间距 1])。对于全队列,R=0.64,在敏感性分析亚组中,R=0.70,主要是由于 s 减少。对于初级保健中的 COPD 患者,嗜酸性粒细胞计数在 1 年内具有较好的可重复性,在排除服用全身皮质类固醇或抗生素的患者后可增加。